Adherence to chronic therapy among patients treated for hypertension, dyslipidemia, or both

Schwartz, Jacob; McLaughlin, Trent; Griffis, Deborah; Arnold, A P Jonathan; Pettitt, Daniel

doi:10.1016/s0735-1097(03)82827-9

Cited by 13 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While patients 65 years and older tended to have higher rates of comorbidity and health services use, no striking differences in patterns of compliance with AH or LL medications were observed between subjects younger than 65 years and those 65 years and older. The pattern of adherence observed in this study-a sharp decline in the first 6 months, followed by a more gradual decline over time-is consistent with previous longitudinal studies 13,19,20 of adherence with AH or LL therapies. However, the rates of adherence observed in this study with concomitant AH and LL therapies, and with AH or LL therapy alone, were higher than those reported in previous studies [12][13][14] that assessed adherence to either AH or LL medications.…”

Section: Commentsupporting

confidence: 91%

Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy

Chapman¹,

Benner²,

Petrilla³

et al. 2005

Arch Intern Med

450

269

View full text Add to dashboard Cite

show abstract

Section: Commentsupporting

confidence: 91%

Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy

Chapman¹,

Benner²,

Petrilla³

et al. 2005

Arch Intern Med

450

269

View full text Add to dashboard Cite

show abstract

“…Furthermore, a cardiovascular polypill could improve adher ence to therapy, which is a major problem for patients who take multiple, separate pills. 40,41 However, the pharmaceutical development of a cardiovascular polypill presents specific peculiari ties and unique challenges. A careful evaluation of the project, which takes into account all of the variables that have a role in the development of a cardiovascular polypill, and a well thoughtout development plan are crucial to maximize the chances of success.…”

Section: Discussionmentioning

confidence: 99%

Issues to consider in the pharmaceutical development of a cardiovascular polypill

Guglietta

Guerrero

2008

Nat Rev Cardiol

View full text Add to dashboard Cite

The pharmaceutical development of a cardiovascular polypill presents several unique challenges. The selection of the type and number of active drugs to be incorporated requires important consideration of clinical, pharmaceutical and commercial issues, and the final decision with regard to the polypill's components depends on how these issues are prioritized. Once the drug combination has been chosen, developers must determine which pharmaceutical formulation should be used. The most appropriate method of drug delivery can vary markedly and depends on the characteristics of the drugs to be combined. Finally, careful consideration of how to gather the type of information required by regulatory agencies before a particular polypill can be approved for use in the general population is crucial. Although the association of multiple, active ingredients in a single dosage form would represent a major step forward in the prevention of cardiovascular conditions, a careful evaluation of all the above-mentioned variables and a well thought-out development plan is mandatory to maximize the chances of success.

show abstract

“…18 Adherence declines most rapidly during the first 6 months of concomitant AH and DL therapy, suggesting the importance of early interventions to maintain or improve adherence. 19 Similarly, adherence is best when AH and DL therapies are initiated on or about the same time, suggesting benefi t from concomitant initiation of therapy to treat these two CVD risk factors.…”

Section: Determinants Of Adherencementioning

confidence: 99%

Patient adherence and preference considerations in managing cardiovascular risk: focus on single pill and amlodipine/atorvastatin fixed combination

Aslam

Haque²,

Lee³

et al. 2009

PPA

View full text Add to dashboard Cite

Cardiovascular disease (CVD) accounts for in excess of 930,000 deaths in the United States each year. Risk factors for CVD often co-exist. Studies estimate that over half of the hypertensive population also has dyslipidemia. Observational data suggest that fewer than 10% of patients attain recommended therapeutic targets for both conditions. A variety of patient, regimen and system characteristics have been associated with the risk for non-adherence. Polypharmacy and complex drug regimens are associated with poor patient adherence and thus the use of fi xed-dose combination therapies, may improve adherence by reducing the pill burden. The fi xed-dose combination of amlodipine/atorvastatin offers a convenient and effective approach to manage two important CVD risk factors. The combination of amlodipine/atorvastatin has a synergistic effect. The half-life of both agents facilitates once-daily dosing and both can be administered at any time of the day with or without food. Amlodipine/atorvastatin combined pill can be used to initiate both agents or patients can be switched directly from single-agent therapy with one or both agents. The convenience of single-pill amlodipine/atorvastatin has the potential to improve patient adherence and the management of cardiovascular risk in selected patients, thereby improving clinical outcomes.

show abstract

Adherence to chronic therapy among patients treated for hypertension, dyslipidemia, or both

Cited by 13 publications

References 0 publications

Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy

Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy

Issues to consider in the pharmaceutical development of a cardiovascular polypill

Patient adherence and preference considerations in managing cardiovascular risk: focus on single pill and amlodipine/atorvastatin fixed combination

Contact Info

Product

Resources

About